Search

Your search keyword '"Parameswaran N"' showing total 1,416 results
Start Over Author "Parameswaran N"

Refine your results

more »

more »

more »

more »

more »
1,416 results on '"Parameswaran N"'

1. Randomized, placebo‐controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomib

Author

Paul G. Richardson, Arnon Nagler, Dina Ben‐Yehuda, Ashraf Badros, Parameswaran N. Hari, Roman Hajek, Ivan Spicka, Hakan Kaya, Richard LeBlanc, Sung‐Soo Yoon, Kihyun Kim, Joaquin Martinez‐Lopez, Moshe Mittelman, Ofer Shpilberg, Paul Blake, Teru Hideshima, Kathleen Colson, Jacob P. Laubach, Irene M. Ghobrial, Merav Leiba, Moshe E. Gatt, Peter Sportelli, Michael Chen, and Kenneth C. Anderson

Subjects
Akt inhibition, bortezomib, multiple myeloma, perifosine, proteasome inhibition, Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

Abstract Perifosine, an investigational, oral, synthetic alkylphospholipid, inhibits signal transduction pathways of relevance in multiple myeloma (MM) including PI3K/Akt. Perifosine demonstrated anti‐MM activity in preclinical studies and encouraging early‐phase clinical activity in combination with bortezomib. A randomized, double‐blind, placebo‐controlled phase 3 study was conducted to evaluate addition of perifosine to bortezomib‐dexamethasone in MM patients with one to four prior therapies who had relapsed following previous bortezomib‐based therapy. The primary endpoint was progression‐free survival (PFS). The study was discontinued at planned interim analysis, with 135 patients enrolled. Median PFS was 22.7 weeks (95% confidence interval 16·0–45·4) in the perifosine arm and 39.0 weeks (18.3–50.1) in the placebo arm (hazard ratio 1.269 [0.817–1.969]; P = .287); overall response rates were 20% and 27%, respectively. Conversely, median overall survival (OS) was 141.9 weeks and 83.3 weeks (hazard ratio 0.734 [0.380–1.419]; P = .356). Overall, 61% and 55% of patients in the perifosine and placebo arms reported grade 3/4 adverse events, including thrombocytopenia (26% vs 14%), anemia (7% vs 8%), hyponatremia (6% vs 8%), and pneumonia (9% vs 3%). These findings demonstrate no PFS benefit from the addition of perifosine to bortezomib‐dexamethasone in this study of relapsed/refractory MM, but comparable safety and OS.

Published
2020
Full Text
View/download PDF

2. Assessment of Molecular Residual Disease Using Circulating Tumor DNA to Identify Multiple Myeloma Patients at High Risk of Relapse

Author

Binod Dhakal, Shruti Sharma, Mustafa Balcioglu, Svetlana Shchegrova, Meenakshi Malhotra, Bernhard Zimmermann, Paul R. Billings, Alexandra Harrington, Himanshu Sethi, Alexey Aleshin, and Parameswaran N. Hari

Subjects
circulating tumor DNA (ctDNA), tumor-informed, minimal/molecular residual disease, multiple myeloma (MM), multiparameter flow cytometry (MFC), Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

BackgroundDespite treatment with high-dose chemotherapy followed by autologous stem cell transplantation (AHCT), patients with multiple myeloma (MM) invariably relapse. Molecular residual disease (MRD)-negativity post-AHCT has emerged as an important prognostic marker predicting the duration of remission. Current techniques for MRD assessment involve bone marrow (BM) aspirate sampling, which is invasive, subject to sample variability and is limited by spatial heterogeneity. We compared the performance of a non-invasive, circulating tumor DNA (ctDNA)-based MRD assay with multiparameter flow cytometry (MFC) of marrow aspirate to predict relapse in AHCT recipients with MM.MethodsMRD assessment using ctDNA was retrospectively analyzed on 80 plasma samples collected at different time points from 28 patients, post-AHCT. MFC was used to assess MRD from BM biopsy. Individual archived BM aspirate slides or formalin-fixed paraffin-embedded slides from the time of MM diagnosis and matched blood were used to assess MRD at 3 months, post-AHCT, using a personalized, tumor-informed ctDNA assay.ResultsctDNA was detectable in 70.8% (17/24) of pre-AHCT patients and 53.6% (15/28) of post-AHCT patients (3-month time point). Of the 15 post-AHCT ctDNA-positive patients, 14 relapsed on follow-up. The median PFS for ctDNA-positive patients was 31 months, and that for ctDNA-negative patients was 84 months (HR: 5.6; 95%CI: 1.8-17;p=0.0003). No significant difference in PFS was observed in patients stratified by MFC-based MRD status (HR 1.2; 95%CI: 0.3-3.4;p=0.73). The positive predictive value for ctDNA was also significantly higher than MFC (93.3% vs. 68.4%).ConclusionsThis study demonstrates tumor-informed ctDNA analysis is strongly predictive of MM relapse.

Published
2022
Full Text
View/download PDF

3. Gut microbiome and CAR-T therapy

Author

Muhammad Bilal Abid, Nirav N. Shah, Theresa C. Maatman, and Parameswaran N. Hari

Subjects
Immunotherapy, Immuno-oncology, CAR T-cells, TRUCKs, Gut microbiome, Dysbiosis, Diseases of the blood and blood-forming organs, RC633-647.5, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Considerable progress has been made in cancer therapeutics recently with targeted strategies that are efficacious and less toxic. Immunotherapy and chimeric antigen receptor (CAR) T-cells are increasingly being evaluated in a variety of tumors in the relapsed/refractory as well as frontline disease settings, predominantly in hematologic malignancies (HM). Despite impressive outcomes in select patients, there remains significant heterogeneity in clinical response to CAR T-cells. The gut microbiome has emerged as one of the key host factors that could potentially be modulated to enhance responses to immunotherapy. Several recent human studies receiving immunotherapy showed a significantly superior response and survival in patients with the more diverse gut microbiome. Currently, it is unknown if gut microbiota modulates anti-tumor responses to CAR T-cells. Based on molecular and immunological understanding, we hypothesize that strategically manipulating gut microbiota may enhance responses to CAR T-cells. In this review, we further discuss resistance mechanisms to CAR T-cells in HM, potential approaches to overcome resistance by harnessing gut microbiota and other related novel strategies.

Published
2019
Full Text
View/download PDF

4. Adjuvant doxycycline to enhance anti-amyloid effects: Results from the dual phase 2 trial

Author

Anita D'Souza, Aniko Szabo, Kathryn E. Flynn, Binod Dhakal, Saurabh Chhabra, Marcelo C. Pasquini, Dorothee Weihrauch, and Parameswaran N. Hari

Subjects
Doxycycline, Systemic light chain amyloidosis, Early mortality, Medicine (General), R5-920
Abstract

Background: Although, doxycycline use is associated with improved outcomes in amyloidosis in retrospective studies, evidence from clinical trials is limited. Methods: This phase 2 trial of doxycycline (clinicaltrials.gov: NCT02207556) in newly diagnosed light chain (AL) amyloidosis enrolled 25 patients with systemic AL amyloidosis on treatment with doxycycline for 1 year along with chemotherapy. Outcomes of interest included mortality, organ response, and hematologic response rates at 1 year. Findings: The median age was 62 years, 64% were male, and 68% had the AL lambda subtype. Patients had Mayo 2012 stage 3 in 24% and stage 4 in 28%. Cardiac involvement was present in 60% of patients, renal involvement in 72%, and 60% patients had 3 or more organs involved. Target organ was cardiac in 14(56%), renal in 7(28%), hepatic in 1(4%) and soft tissue in 3(12%). At 1 year, mortality was 20% (95% confidence interval, 8.9–41.6%) and organ response was 36% (18–57%). Hematologic response in 1-year survivors was 100%, including 30% complete and 55% very good partial response. Autologous hematopoietic cell transplant was performed in 60%; among transplanted patients, day-100 transplant-related mortality was 0. Doxycycline use was safe and not attributed to any grade 2 or higher toxicity. Interpretation: In addition to a low 1-year mortality, doxycycline use was safe and associated with high transplant utilization rate. We thus contend that doxycycline should be studied in a placebo-controlled study in newly diagnosed AL patients in the first year, particularly among patients with advanced disease and cardiac involvement.

Published
2020
Full Text
View/download PDF

5. Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at one year compared to unrelated donors

Author

Michael A. Pulsipher, Brent R. Logan, Deidre M. Kiefer, Pintip Chitphakdithai, Marcie L. Riches, J. Douglas Rizzo, Paolo Anderlini, O’Susan F. Leitman, Hati Kobusingye, RaeAnne M. Besser, John P. Miller, Rebecca J. Drexler, Aly Abdel-Mageed, Ibrahim A. Ahmed, Luke P. Akard, Andrew S. Artz, Edward D. Ball, Ruthee-Lu Bayer, Carolyn Bigelow, Brian J. Bolwell, E. Randolph Broun, David C. Delgado, Katharine Duckworth, Christopher C. Dvorak, Theresa E. Hahn, Ann E. Haight, Parameswaran N. Hari, Brandon M. Hayes-Lattin, David A. Jacobsohn, Ann A. Jakubowski, Kimberly A. Kasow, Hillard M. Lazarus, Jane L. Liesveld, Michael Linenberger, Mark R. Litzow, Walter Longo, Margarida Magalhaes-Silverman, John M. McCarty, Joseph P. McGuirk, Shahram Mori, Vinod Parameswaran, Vinod K. Prasad, Scott D. Rowley, Witold B. Rybka, Indira Sahdev, Jeffrey R. Schriber, George B. Selby, Paul J. Shaughnessy, Shalini Shenoy, Thomas Spitzer, William T. Tse, Joseph P. Uberti, Madhuri Vusirikala, Edmund K. Waller, Daniel J. Weisdorf, Gregory A. Yanik, Willis H. Navarro, Mary M. Horowitz, Galen E. Switzer, Dennis L. Confer, and Bronwen E. Shaw

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

Unlike unrelated donor registries, transplant centers lack uniform approaches to related donor assessment and deferral. To test whether related donors are at increased risk for donation-related toxicities, we conducted a prospective observational trial of 11,942 related and unrelated donors aged 18–60 years. Bone marrow (BM) was collected at 37 transplant and 78 National Marrow Donor Program centers, and peripheral blood stem cells (PBSC) were collected at 42 transplant and 87 unrelated donor centers in North America. Possible presence of medical comorbidities was verified prior to donation, and standardized pain and toxicity measures were assessed pre-donation, peri-donation, and one year following. Multivariate analyses showed similar experiences for BM collection in related and unrelated donors; however, related stem cell donors had increased risk of moderate [odds ratios (ORs) 1.42; P

Published
2019
Full Text
View/download PDF

6. Outcomes of upfront autologous hematopoietic cell transplantation in patients with multiple myeloma who are 75 years old or older

Author

Munshi, Pashna N, Vesole, David H, St. Martin, Andrew, Davila, Omar, Kumar, Shaji, Qazilbash, Muzaffar, Shah, Nina, Hari, Parameswaran N, and D’Souza, Anita

Subjects
Transplantation, Clinical Research, Regenerative Medicine, Hematology, Good Health and Well Being, Aged, Female, Hematopoietic Stem Cell Transplantation, Humans, Male, Melphalan, Multiple Myeloma, Neoplasm Recurrence, Local, Transplantation Conditioning, Transplantation, Autologous, Treatment Outcome, United States, elderly, hematopoietic, myeloma, transplantation, utilization, Oncology and Carcinogenesis, Public Health and Health Services, Oncology & Carcinogenesis
Abstract

BackgroundConsolidative autologous hematopoietic stem cell transplantation (AHCT) is commonly used for patients with multiple myeloma (MM). We studied AHCT use and outcomes in patients with MM ≥75 years old.MethodsPatients with MM ≥75 years old receiving AHCT between 2013 and 2017 in the United States were identified using the Center for International Blood and Marrow Transplant Research database. Relapse and/or progression (REL), progression-free survival (PFS), and overall survival (OS) were modeled using Cox proportional hazards models. Covariates used were age, sex, Karnofsky performance score (KPS), HCT-comorbidity index (HCT-CI), International Staging System and/or Durie-Salmon stage, high-risk cytogenetics, melphalan dose, and disease status at and 1 year after transplant. AHCT utilization rate using the Surveillance, Epidemiology, and End Results database was used to estimate specific incidence among ≥75 years old by race and gender.ResultsOf 360 patients, 63% were male, 84% were White, 56% had KPS

Published
2021

7. Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at one year compared to unrelated donors

Author

Pulsipher, Michael A, Logan, Brent R, Kiefer, Deidre M, Chitphakdithai, Pintip, Riches, Marcie L, Rizzo, J Douglas, Anderlini, Paolo, Leitman, O’Susan F, Kobusingye, Hati, Besser, RaeAnne M, Miller, John P, Drexler, Rebecca J, Abdel-Mageed, Aly, Ahmed, Ibrahim A, Akard, Luke P, Artz, Andrew S, Ball, Edward D, Bayer, Ruthee-Lu, Bigelow, Carolyn, Bolwell, Brian J, Broun, E Randolph, Delgado, David C, Duckworth, Katharine, Dvorak, Christopher C, Hahn, Theresa E, Haight, Ann E, Hari, Parameswaran N, Hayes-Lattin, Brandon M, Jacobsohn, David A, Jakubowski, Ann A, Kasow, Kimberly A, Lazarus, Hillard M, Liesveld, Jane L, Linenberger, Michael, Litzow, Mark R, Longo, Walter, Magalhaes-Silverman, Margarida, McCarty, John M, McGuirk, Joseph P, Mori, Shahram, Parameswaran, Vinod, Prasad, Vinod K, Rowley, Scott D, Rybka, Witold B, Sahdev, Indira, Schriber, Jeffrey R, Selby, George B, Shaughnessy, Paul J, Shenoy, Shalini, Spitzer, Thomas, Tse, William T, Uberti, Joseph P, Vusirikala, Madhuri, Waller, Edmund K, Weisdorf, Daniel J, Yanik, Gregory A, Navarro, Willis H, Horowitz, Mary M, Switzer, Galen E, Confer, Dennis L, and Shaw, Bronwen E

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Transplantation, Patient Safety, Regenerative Medicine, Clinical Research, Neurosciences, Stem Cell Research - Nonembryonic - Human, Chronic Pain, Pain Research, Stem Cell Research, Adolescent, Adult, Female, Humans, Living Donors, Male, Middle Aged, Peripheral Blood Stem Cell Transplantation, Peripheral Blood Stem Cells, Prospective Studies, Quality of Life, Unrelated Donors, Young Adult, Cardiorespiratory Medicine and Haematology, Immunology, Cardiovascular medicine and haematology
Abstract

Unlike unrelated donor registries, transplant centers lack uniform approaches to related donor assessment and deferral. To test whether related donors are at increased risk for donation-related toxicities, we conducted a prospective observational trial of 11,942 related and unrelated donors aged 18-60 years. Bone marrow (BM) was collected at 37 transplant and 78 National Marrow Donor Program centers, and peripheral blood stem cells (PBSC) were collected at 42 transplant and 87 unrelated donor centers in North America. Possible presence of medical comorbidities was verified prior to donation, and standardized pain and toxicity measures were assessed pre-donation, peri-donation, and one year following. Multivariate analyses showed similar experiences for BM collection in related and unrelated donors; however, related stem cell donors had increased risk of moderate [odds ratios (ORs) 1.42; P

Published
2019

8. Effect of Aging and Predonation Comorbidities on the Related Peripheral Blood Stem Cell Donor Experience: Report from the Related Donor Safety Study.

Author

Pulsipher, Michael A, Logan, Brent R, Chitphakdithai, Pintip, Kiefer, Deidre M, Riches, Marcie L, Rizzo, J Douglas, Anderlini, Paolo, Leitman, Susan F, Varni, James W, Kobusingye, Hati, Besser, RaeAnne M, Miller, John P, Drexler, Rebecca J, Abdel-Mageed, Aly, Ahmed, Ibrahim A, Akard, Luke P, Artz, Andrew S, Ball, Edward D, Bayer, Ruthee-Lu, Bigelow, Carolyn, Bolwell, Brian J, Broun, E Randolph, Bunin, Nancy J, Delgado, David C, Duckworth, Katharine, Dvorak, Christopher C, Hahn, Theresa E, Haight, Ann E, Hari, Parameswaran N, Hayes-Lattin, Brandon M, Jacobsohn, David A, Jakubowski, Ann A, Kasow, Kimberly A, Lazarus, Hillard M, Liesveld, Jane L, Linenberger, Michael, Litzow, Mark R, Longo, Walter, Magalhaes-Silverman, Margarida, McCarty, John M, McGuirk, Joseph P, Mori, Shahram, Prasad, Vinod K, Rowley, Scott D, Rybka, Witold B, Sahdev, Indira, Schriber, Jeffrey R, Selby, George B, Shaughnessy, Paul J, Shenoy, Shalini, Spitzer, Thomas, Tse, William T, Uberti, Joseph P, Vusirikala, Madhuri, Waller, Edmund K, Weisdorf, Daniel J, Yanik, Gregory A, Navarro, Willis H, Horowitz, Mary M, Switzer, Galen E, Shaw, Bronwen E, and Confer, Dennis L

Subjects
Humans, Peripheral Blood Stem Cell Transplantation, Comorbidity, Adolescent, Adult, Aged, Middle Aged, Blood Donors, Female, Male, Young Adult, Peripheral Blood Stem Cells, BM collection toxicities, Donor safety, PBSC collection toxicities, Stem cell transplantation, Transplantation, Pain Research, Stem Cell Research - Nonembryonic - Human, Clinical Research, Chronic Pain, Stem Cell Research, Aging, Clinical Sciences, Immunology
Abstract

The development of reduced-intensity approaches for allogeneic hematopoietic cell transplantation has resulted in growing numbers of older related donors (RDs) of peripheral blood stem cells (PBSCs). The effects of age on donation efficacy, toxicity, and long-term recovery in RDs are poorly understood. To address this we analyzed hematologic variables, pain, donation-related symptoms, and recovery in 1211 PBSC RDs aged 18 to 79 enrolled in the Related Donor Safety Study. RDs aged > 60 had a lower median CD34+ level before apheresis compared with younger RDs (age > 60, 59 × 106/L; age 41 to 60, 81 × 106/L; age 18 to 40, 121 × 106/L; P < .001). This resulted in older donors undergoing more apheresis procedures (49% versus 30% ≥ 2 collections, P < .001) and higher collection volumes (52% versus 32% > 24 L, P < .001), leading to high percentages of donors aged > 60 with postcollection thrombocytopenia

Published
2019

12. Ixazomib for Chronic Graft-versus-Host Disease Prophylaxis following Allogeneic Hematopoietic Cell Transplantation

Author

Chhabra, Saurabh, Visotcky, Alexis, Pasquini, Marcelo C., Zhu, Fenlu, Tang, Xiaoying, Zhang, Mei-Jie, Thompson, Robert, Abedin, Sameem, D'Souza, Anita, Dhakal, Binod, Drobyski, William R., Fenske, Timothy S., Jerkins, James H., Douglas Rizzo, J., Runaas, Lyndsey, Saber, Wael, Shah, Nirav N., Shaw, Bronwen E., Horowitz, Mary M., Hari, Parameswaran N., and Hamadani, Mehdi

Published
2020
Full Text
View/download PDF

17. Fludarabine/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes

Author

Chhabra, Saurabh, Narra, Ravi K., Wu, Ruizhe, Szabo, Aniko, George, Gemlyn, Michaelis, Laura C., D'Souza, Anita, Dhakal, Binod, Drobyski, William R., Fenske, Timothy S., Jerkins, James H., Pasquini, Marcelo C., Rizzo, R. Douglas, Saber, Wael, Shah, Nirav N., Shaw, Bronwen E., Hamadani, Mehdi, and Hari, Parameswaran N.

Published
2020
Full Text
View/download PDF

19. New Cancers after Autotransplantations for Multiple Myeloma

Author

Mahindra, Anuj, Raval, Girindra, Mehta, Paulette, Brazauskas, Ruta, Zhang, Mei-Jie, Zhong, Xiaobo, Bird, Jennifer M, Freytes, César O, Hale, Gregory A, Herzig, Roger, Holmberg, Leona A, Kamble, Rammurti T, Kumar, Shaji, Lazarus, Hillard M, Majhail, Navneet S, Marks, David I, Moreb, Jan S, Olsson, Richard, Saber, Wael, Savani, Bipin N, Schiller, Gary J, Tay, Jason, Vogl, Dan T, Waller, Edmund K, Wiernik, Peter H, Wirk, Baldeep, Lonial, Sagar, Krishnan, Amrita Y, Dispenzieri, Angela, Brandenburg, Nancy A, Gale, Robert Peter, and Hari, Parameswaran N

Subjects
Cancer, Rare Diseases, Clinical Research, Hematology, Adolescent, Autografts, Child, Child, Preschool, Female, Humans, Incidence, Infant, Infant, Newborn, Male, Multiple Myeloma, Neoplasms, Second Primary, Retrospective Studies, Risk Factors, Sex Factors, Stem Cell Transplantation, United States, Myeloma, Second cancer, Transplantation, Clinical Sciences, Immunology
Abstract

We describe baseline incidence and risk factors for new cancers in 4161 persons receiving autotransplants for multiple myeloma in the United States from 1990 to 2010. Observed incidence of invasive new cancers was compared with expected incidence relative to the US population. The cohort represented 13,387 person-years at-risk. In total, 163 new cancers were observed, for a crude incidence rate of 1.2 new cancers per 100 person-years and cumulative incidences of 2.6% (95% confidence interval [CI], 2.09 to 3.17), 4.2% (95% CI, 3.49 to 5.00), and 6.1% (95% CI, 5.08 to 7.24) at 3, 5, and 7 years, respectively. The incidence of new cancers in the autotransplantation cohort was similar to age-, race-, and gender-adjusted comparison subjects with an observed/expected (O/E) ratio of 1.00 (99% CI, .81 to 1.22). However, acute myeloid leukemia and melanoma were observed at higher than expected rates with O/E ratios of 5.19 (99% CI, 1.67 to 12.04; P = .0004), and 3.58 (99% CI, 1.82 to 6.29; P < .0001), respectively. Obesity, older age, and male gender were associated with increased risks of new cancers in multivariate analyses. This large data set provides a baseline for comparison and defines the histologic type specific risk for new cancers in patients with MM receiving postautotransplantation therapies, such as maintenance.

Published
2015

21. Re-engineering Public Library services for the networked community in the Indian context

Author

Parameswaran, N. and Vimal Kumar, V.

Subjects
DC. Public libraries.
Abstract

Public libraries have a social mission which involves in providing collections and services to meet a community’s information needs. They exist to serve communities. It is the local gate way to knowledge and provides a basic condition for life long learning, independent decision making and cultural development of the individual and social groups. But tremendous changes in the Information and Communication Technology and changing life style has greatly influenced the information seeking behavior of the library users. Library services based on the conventional service model lack the new information services and there exist a large gap between user needs and actual library service. The public library services should be re-engineered to meet the changing atmosphere. The paper stresses that the library leaders must have the skills to create and nurture a new type of library culture in which changeis encouraged and new visions of service implemented. It opines that a new focus on the needs of non traditional library users has also become necessary to attract the community.

Published
2008

27. Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation

Author

Kanate, Abraham S., Hari, Parameswaran N., Pasquini, Marcelo C., Visotcky, Alexis, Ahn, Kwang W., Boyd, Jennifer, Guru Murthy, Guru Subramanian, Rizzo, J. Douglas, Saber, Wael, Drobyski, William, Michaelis, Laura, Atallah, Ehab, Carlson, Karen S., D'Souza, Anita, Fenske, Timothy S., Cumpston, Aaron, Bunner, Pamela, Craig, Michael, Horowitz, Mary M., and Hamadani, Mehdi

Published
2017
Full Text
View/download PDF

31. Policy-Based Energy Management in Smart Homes

Author

Anandalakshmi, T. K., Sathiakumar, S., Parameswaran, N., Kacprzyk, Janusz, Series editor, Sathiakumar, Swamidoss, editor, Awasthi, Lalit Kumar, editor, Masillamani, M. Roberts, editor, and Sridhar, S S, editor

Published
2014
Full Text
View/download PDF

35. Contributors

Author

Abdel-Wahab, Omar, primary, Abrahm, Janet L., additional, Adams, Sharon, additional, Adewoye, Adeboye H., additional, Allen, Carl, additional, Ambinder, Richard F., additional, Anasetti, Claudio, additional, Anastasi, John, additional, Anderson, Julia A., additional, Antin, Joseph H., additional, Antony, Aśok C., additional, Araten, David J., additional, Armand, Philippe, additional, Armstrong, Gillian, additional, Armstrong, Scott A., additional, Arnold, Donald M., additional, Artz, Andrew S., additional, Awan, Farrukh T., additional, Baglin, Trevor P., additional, Benson, Don M., additional, Benz, Edward J., additional, Berliner, Nancy, additional, Bhagat, Govind, additional, Bhardwaj, Nina, additional, Bhatia, Ravi, additional, Bhatia, Smita, additional, Bhatt, Mihir D., additional, Bhatt, Vijaya Raj, additional, Bitan, Menachem, additional, Blinderman, Craig D., additional, Bollard, Catherine M., additional, Braun, Benjamin S., additional, Brenner, Malcolm K., additional, Brittenham, Gary M., additional, Brodsky, Robert A., additional, Brown, Myles, additional, Broxmeyer, Hal E., additional, Brummel-Ziedins, Kathleen, additional, Brunner, Andrew M., additional, Buadi, Francis K., additional, Burkhardt, Birgit, additional, Burns, Melissa, additional, Byrd, John C., additional, Caimi, Paolo F., additional, Caligiuri, Michael A., additional, Canavan, Michelle, additional, Cantor, Alan B., additional, Carcao, Manuel, additional, Carroll, Michael C., additional, Carty, Shannon A., additional, Castillo, Jorge J., additional, Chan, Anthony K.C., additional, Chapin, John, additional, Chiu, April, additional, Chute, John P., additional, Clark, David B., additional, Coates, Thomas D., additional, Cogle, Christopher R., additional, Connell, Nathan T., additional, Cooke, Elizabeth, additional, Cooley, Sarah, additional, Corradini, Paolo, additional, Creager, Mark A., additional, Creger, Richard J., additional, Cromwell, Caroline, additional, Crowther, Mark A., additional, Cushing, Melissa M., additional, Cutler, Corey, additional, Dang, Chi V., additional, Danial, Nika N., additional, Dave, Sandeep S., additional, DeCaprio, James A., additional, Dinauer, Mary C., additional, Dinner, Shira, additional, Diz-Küçükkaya, Reyhan, additional, Dodd, Roger Y., additional, Donato, Michele L., additional, Dorshkind, Kenneth, additional, Dotti, Gianpietro, additional, Dror, Yigal, additional, Dunleavy, Kieron, additional, Dvorak, Christopher C., additional, Ebert, Benjamin L., additional, Eck, Michael J., additional, Eikelboom, John W., additional, Epperla, Narendranath, additional, Ershler, William B., additional, Evans, William E., additional, Faderl, Stefan, additional, Ferrara, James L.M., additional, Filipovich, Alexandra Hult, additional, Fischer, Martin, additional, Fredenburgh, James C., additional, Friedman, Kenneth D., additional, Fuchs, Ephraim, additional, Fuller, Stephen J., additional, Gailani, David, additional, Galipeau, Jacques, additional, Gallagher, Patrick G., additional, Ganapathi, Karthik A., additional, Gardner, Lawrence B., additional, Gee, Adrian P., additional, Gerson, Stanton L., additional, Gertz, Morie A., additional, Giardina, Patricia J., additional, Gibson, Christopher J., additional, Golan, Karin, additional, Golub, Todd R., additional, Gonzales, Matthew J., additional, Gotlib, Jason, additional, Gottschalk, Stephen, additional, Grant, Marianne A., additional, Graubert, Timothy A., additional, Gregg, Xylina T., additional, Gribben, John G., additional, Gross, Dawn M., additional, Gruber, Tanja A., additional, Guitart, Joan, additional, Gurbuxani, Sandeep, additional, Gur-Cohen, Shiri, additional, Gutierrez, Alejandro, additional, Hamadani, Mehdi, additional, Hari, Parameswaran N., additional, Hartwig, John H., additional, Hayman, Suzanne R., additional, Hayward, Catherine P.M., additional, Hebbel, Robert P., additional, Heslop, Helen E., additional, Hillis, Christopher, additional, Hillyer, Christopher D., additional, Ho, Karin, additional, Hockenbery, David M., additional, Hoffman, Ronald, additional, Hogg, Kerstin E., additional, Holtan, Shernan G., additional, Horny, Hans-Peter, additional, Hsu, Yen-Michael S., additional, Hunter, Zachary R., additional, Huntington, James A., additional, Iancu-Rubin, Camelia, additional, Iqbal, Ali, additional, Isenman, David E., additional, Israels, Sara J., additional, Italiano, Joseph E., additional, Jaffe, Elaine S., additional, Jaffer, Iqbal H., additional, Jagannath, Sundar, additional, Jäger, Ulrich, additional, Jain, Nitin, additional, James, Paula, additional, Jeha, Sima, additional, Jordan, Michael B., additional, Josephson, Cassandra D., additional, Jung, Moonjung, additional, Kager, Leo, additional, Kambayashi, Taku, additional, Kanakry, Jennifer A., additional, Kantarjian, Hagop M., additional, Kaplan, Jason, additional, Karafin, Matthew S., additional, Karsan, Aly, additional, Kaufman, Randal J., additional, Kaufman, Richard M., additional, Keller, Frank G., additional, Kelly, Kara M., additional, Kessler, Craig M., additional, Key, Nigel S., additional, Keyzner, Alla, additional, Khandoga, Alexander G., additional, Khanna-Gupta, Arati, additional, Khatib-Massalha, Eman, additional, Klein, Harvey G., additional, Knoechel, Birgit, additional, Kollet, Orit, additional, Konkle, Barbara A., additional, Kontoyiannis, Dimitrios P., additional, Koreth, John, additional, Koretzky, Gary A., additional, Kotecha, Dipak, additional, Kremyanskaya, Marina, additional, Kumari, Anju, additional, Kuzel, Timothy M., additional, Küppers, Ralf, additional, Lacy, Martha Q., additional, Ladas, Elana, additional, Landier, Wendy, additional, Lapid, Kfir, additional, Lapidot, Tsvee, additional, Larson, Peter J., additional, Levi, Marcel, additional, Lewis, Russell E., additional, Liebman, Howard A., additional, Lillicrap, David, additional, Lim, Wendy, additional, Lin, Judith C., additional, Lindblad, Robert, additional, Lip, Gregory Y.H., additional, Little, Jane A., additional, Lohr, Jens G., additional, López, José A., additional, Luscinskas, Francis W., additional, Maciejewski, Jaroslaw P., additional, Majhail, Navneet S., additional, Manches, Olivier, additional, Mandle, Robert J., additional, Mann, Kenneth G., additional, Manno, Catherine S., additional, Marcogliese, Andrea N., additional, Mariani, Guglielmo, additional, Marincola, Francesco M., additional, Mascarenhas, John, additional, Massberg, Steffen, additional, McEver, Rodger P., additional, McGrath, Emer, additional, McKinney, Matthew S., additional, Mehta, Rohtesh S., additional, Mentzer, William C., additional, Merlini, Giampaolo, additional, Merryman, Reid, additional, Michel, Marc, additional, Migliaccio, Anna Rita, additional, Miller, Jeffrey S., additional, Mims, Martha P., additional, Mondoro, Traci Heath, additional, Moorehead, Paul, additional, Muniz, Luciana R., additional, Munshi, Nikhil C., additional, Najfeld, Vesna, additional, Nayak, Lalitha, additional, Nazy, Ishac, additional, Neff, Anne T., additional, Ness, Paul M., additional, Notarangelo, Luigi D., additional, O'Brien, Sarah H., additional, O'Connor, Owen A., additional, O'Donnell, Martin, additional, Olson, Amanda, additional, Orkin, Stuart H., additional, Pai, Menaka, additional, Pai, Sung-Yun, additional, Paidas, Michael, additional, Panch, Sandhya R., additional, Pande, Reena L., additional, Papayannopoulou, Thalia, additional, Parikh, Rahul, additional, Petersdorf, Effie W., additional, Peterson, Shane E., additional, Pittaluga, Stefania, additional, Ponce, Doris M., additional, Popolo, Laura, additional, Prchal, Josef T., additional, Pui, Ching-Hon, additional, Puigserver, Pere, additional, Rak, Janusz, additional, Ramos, Carlos A., additional, Rand, Jacob H., additional, Rand, Margaret L., additional, Rao, Dinesh S., additional, Ravandi, Farhad, additional, Rawlings, David J., additional, Reddy, Pavan, additional, Reding, Mark T., additional, Reiter, Andreas, additional, Rice, Lawrence, additional, Riese, Matthew J., additional, Ritchey, Arthur Kim, additional, Roberts, David J., additional, Roman, Elizabeth, additional, Rooney, Cliona M., additional, Rosen, Steven T., additional, Rosenthal, David S., additional, Rossmann, Marlies P., additional, Rot, Antal, additional, Rowley, Scott D., additional, Rubnitz, Jeffrey E., additional, Rydz, Natalia, additional, Salama, Mohamed E., additional, Sauk, Steven, additional, Saunthararajah, Yogen, additional, Savage, William, additional, Scadden, David, additional, Schaefer, Kristen G., additional, Schiffman, Fred, additional, Schneidewend, Robert, additional, Schrier, Stanley L., additional, Schuchman, Edward H., additional, Scullion, Bridget Fowler, additional, Selvaggi, Kathy J., additional, Senoo, Keitaro, additional, Shaheen, Montaser, additional, Shaz, Beth H., additional, Shelburne, Samuel A., additional, Shpall, Elizabeth J., additional, Shurin, Susan B., additional, Siegal, Deborah, additional, Silberstein, Leslie E., additional, Silberstein, Lev, additional, Silverstein, Roy L., additional, Sloan, Steven R., additional, Smith, Franklin O., additional, Smith, James W., additional, Smith, Katy, additional, Steensma, David P., additional, Steinberg, Martin H., additional, Stock, Wendy, additional, Storry, Jill R., additional, Stramer, Susan L., additional, Strauss, Ronald G., additional, Stroncek, David F., additional, Taylor, Justin, additional, Thota, Swapna, additional, Treon, Steven P., additional, Tulpule, Anil, additional, Valdes, Roberto Ferro, additional, Valent, Peter, additional, Vedantham, Suresh, additional, Vercellotti, Gregory M., additional, Verneris, Michael R., additional, Vichinsky, Elliott P., additional, von Andrian, Ulrich H., additional, Vose, Julie M., additional, Wagner, Andrew J., additional, Wang, Ena, additional, Wang, Jia-huai, additional, Warkentin, Theodore E., additional, Wasserstein, Melissa P., additional, Webster, Ann, additional, Weisdorf, Daniel J., additional, Weitz, Jeffrey I., additional, Westhoff, Connie M., additional, Wheeler, Allison P., additional, Widick, Page, additional, Wiley, James S., additional, William, Basem M., additional, Williams, David A., additional, Wilson, Wyndham H., additional, Wolfe, Joanne, additional, Wolgast, Lucia R., additional, Wood, Deborah, additional, Wu, Jennifer, additional, Yahalom, Joachim, additional, Yee, Donald L., additional, Younes, Anas, additional, Young, Neal S., additional, and Zeller, Michelle P., additional

Published
2018
Full Text
View/download PDF

37. Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors

Author

Klyuchnikov, Evgeny, Bacher, Ulrike, Kröger, Nicolaus M., Hari, Parameswaran N., Ahn, Kwang Woo, Carreras, Jeanette, Bachanova, Veronika, Bashey, Asad, Cohen, Jonathon B., D'Souza, Anita, Freytes, César O., Gale, Robert Peter, Ganguly, Siddhartha, Hertzberg, Mark S., Holmberg, Leona A., Kharfan-Dabaja, Mohamed A., Klein, Andreas, Ku, Grace H., Laport, Ginna G., Lazarus, Hillard M., Miller, Alan M., Mussetti, Alberto, Olsson, Richard F., Slavin, Shimon, Usmani, Saad Z., Vij, Ravi, Wood, William A., Maloney, David G., Sureda, Anna M., Smith, Sonali M., and Hamadani, Mehdi

Published
2015
Full Text
View/download PDF

39. Impact of Pretransplant Therapy and Depth of Disease Response before Autologous Transplantation for Multiple Myeloma

Author

Vij, Ravi, Kumar, Shaji, Zhang, Mei-Jie, Zhong, Xiaobo, Huang, Jiaxing, Dispenzieri, Angela, Abidi, Muneer H., Bird, Jennifer M., Freytes, César O., Gale, Robert Peter, Kindwall-Keller, Tamila L., Kyle, Robert A., Landsburg, Daniel J., Lazarus, Hillard M., Munker, Reinhold, Roy, Vivek, Sharma, Manish, Vogl, Dan T., Wirk, Baldeep, and Hari, Parameswaran N.

Published
2015
Full Text
View/download PDF

40. Addressing bias in predictions of global sedimentation rates through physical parameters, few-shot learning, and numerical modeling

Author

Parameswaran, N., Gonzalez, E., Wallmann, K., Bur­wicz-Galerne, E., and Braack, M.

Abstract

The prediction of global sedimentation rates is a critical aspect of comprehending various phenomena, such as carbon sequestration and seafloor stability. With the advent of machine learning, there has been an increasing trend towards utilizing these techniques to predict quantities on the seafloor, including porosity and total organic carbon. Several studies have been conducted to predict sedimentation rates[cm/ka] and mass accumulation rates[Mt/yr] using techniques such as k Nearest Neighbors and neural networks. However, a significant issue with these methods is the observed tendency for the models to over-predict sediment budget, a crucial parameter in evaluating the validity of predictions. This bias may stem from the paucity of low sedimentation rate data points on the continental shelves, where most scientific expeditions concentrate on high sedimentation rate areas. This bias disregards valuable data on low sedimentation rates, which would be useful in developing a comprehensive global map of sedimentation rates. To address this issue, there are several potential methods. The first involves identifying physical parameters, such as porosity, sediment grain size and bottom currents, that correlate with low sedimentation rates and can be utilized to identify these areas. The second involves utilizing few-shot learning, a machine learning technique that allows for training with limited low sedimentation rate labels. The third method involves the use of numerical models in small spatial areas, which can offer further insights into the processes behind low sedimentation rates and provide more data for analysis., The 28th IUGG General Assembly (IUGG2023) (Berlin 2023)

Published
2023
Full Text
View/download PDF

42. Expert Committee on School Libraries

Author

Kerala, Government of, Joy, V P, IAS, Isaac, K A., Parameswaran, N., and Raman Nair, R.

Subjects
DE. School libraries., D. Libraries as physical collections., A. Theoretical and general aspects of libraries and information., F. Management., B. Information use and sociology of information, K. Housing technologies., C. Users, literacy and reading.
Abstract

Kerala has almost achieved the aim of universal access for primary and secondary education. Higher secondary education has also been integrated recently with school education. But a disturbing fact is that education imparted in schools of Kerala is of very poor quality. One major factor leading to this is the absence of library services of required standard. The survey conducted by the committee found that only 20% of the schools in the State have at least a room for keeping books. Due to this children do not pick up the reading habit at the age at which it should be acquired. Lacking the essential equipment needed for life long learning, they become handicapped in critical thinking and forming rational judgments on the problems that they or the society in which they live encounter in life. This is the main source of many ills that plague the school education today. The committee view that quality up gradation in schools is inextricably linked to the setting up and strengthening of school libraries. Library must occupy a central position in the school. With this objective the committee has examined the school education system and suggested various measures to make school libraries vital and vibrant institutions. The main areas on which the recommendations of committee focus are (a) setting up of school libraries, provision of infrastructure and building up a good collection, (b) school librarian’s role and personnel policies to be adopted in manning school libraries (c) administrative and procedural improvement and (d) integration of library with ICT resources for multi sensory learning. The Committee has also proposed standards for various aspects of school libraries and a few building designs that can be adopted to house a system that integrates information and concerned technology in schools.

Published
2002

45. Corrigendum to ‘Ixazomib for chronic Graft-Versus-Host Disease prophylaxis following allogeneic hematopoietic cell transplantation’ [Biology of Blood and Marrow Transplantation 26/10 (2020) 1876-1885]

Author

Chhabra, Saurabh, primary, Visotcky, Alexis, additional, Pasquini, Marcelo C., additional, Zhu, Fenlu, additional, Tang, Xiaoying, additional, Zhang, Mei-Jie, additional, Thompson, Robert, additional, Abedin, Sameem, additional, D'Souza, Anita, additional, Dhakal, Binod, additional, Drobyski, William R., additional, Fenske, Timothy S., additional, Jerkins, James H., additional, Rizzo, J. Douglas, additional, Runaas, Lyndsey, additional, Saber, Wael, additional, Shah, Nirav N., additional, Shaw, Bronwen E., additional, Horowitz, Mary M., additional, Hari, Parameswaran N., additional, and Hamadani, Mehdi, additional

Published
2022
Full Text
View/download PDF

46. Early Failure of Frontline Rituximab-Containing Chemo-immunotherapy in Diffuse Large B Cell Lymphoma Does Not Predict Futility of Autologous Hematopoietic Cell Transplantation

Author

Hamadani, Mehdi, Hari, Parameswaran N., Zhang, Ying, Carreras, Jeanette, Akpek, Görgün, Aljurf, Mahmoud D., Ayala, Ernesto, Bachanova, Veronika, Chen, Andy I., Chen, Yi-Bin, Costa, Luciano J., Fenske, Timothy S., Freytes, César O., Ganguly, Siddhartha, Hertzberg, Mark S., Holmberg, Leona A., Inwards, David J., Kamble, Rammurti T., Kanfer, Edward J., Lazarus, Hillard M., Marks, David I., Nishihori, Taiga, Olsson, Richard, Reddy, Nishitha M., Rizzieri, David A., Savani, Bipin N., Solh, Melhem, Vose, Julie M., Wirk, Baldeep, Maloney, David G., Smith, Sonali M., Montoto, Silvia, and Saber, Wael

Published
2014
Full Text
View/download PDF

47. Hematopoietic Cell Transplant Comorbidity Index Is Predictive of Survival after Autologous Hematopoietic Cell Transplantation in Multiple Myeloma

Author

Saad, Ayman, Mahindra, Anuj, Zhang, Mei-Jie, Zhong, Xiaobo, Costa, Luciano J., Dispenzieri, Angela, Drobyski, William R., Freytes, Cesar O., Gale, Robert Peter, Gasparetto, Cristina J., Holmberg, Leona A., Kamble, Rammurti T., Krishnan, Amrita Y., Kyle, Robert A., Marks, David, Nishihori, Taiga, Pasquini, Marcelo C., Ramanathan, Muthalagu, Lonial, Sagar, Savani, Bipin N., Saber, Wael, Sharma, Manish, Sorror, Mohamed L., Wirk, Baldeep M., and Hari, Parameswaran N.

Published
2014
Full Text
View/download PDF

48. Reduced-Intensity Hematopoietic Cell Transplantation for Patients with Primary Myelofibrosis: A Cohort Analysis from the Center for International Blood and Marrow Transplant Research

Author

Gupta, Vikas, Malone, Adriana K., Hari, Parameswaran N., Ahn, Kwang Woo, Hu, Zhen-Huan, Gale, Robert Peter, Ballen, Karen K., Hamadani, Mehdi, Olavarria, Eduardo, Gerds, Aaron T., Waller, Edmund K., Costa, Luciano J., Antin, Joseph H., Kamble, Rammurti T., van Besien, Koen M., Savani, Bipin N., Schouten, Harry C., Szer, Jeffrey, Cahn, Jean-Yves, de Lima, Marcos J., Wirk, Baldeep, Aljurf, Mahmoud D., Popat, Uday, Bejanyan, Nelli, Litzow, Mark R., Norkin, Maxim, Lewis, Ian D., Hale, Gregory A., Woolfrey, Ann E., Miller, Alan M., Ustun, Celalettin, Jagasia, Madan H., Lill, Michael, Maziarz, Richard T., Cortes, Jorge, Kalaycio, Matt E., and Saber, Wael

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results